Article Text

PDF
Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban
  1. José Luis Marco Garbayo1,
  2. Manuel Koninckx Cañada1,
  3. Isabel Pérez Castelló1,
  4. María Teresa Faus Soler1,
  5. Mariam Perea Ribis2
  1. 1Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Gandia, Valencia, Spain
  2. 2Department of Internal Medicine, Francesc de Borja Hospital of Gandia, Gandia, Valencia, Spain
  1. Correspondence to Dr Manuel Koninckx Cañada, Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Gandia, 46701 Valencia, Spain; koninchk_man{at}gva.es

Abstract

Objectives To analyse the hospital admissions for bleeding events associated with treatment with direct oral anticoagulants (DOACs). To describe the characteristics and outcomes of those patients.

Methods A retrospective observational study was carried out in the framework of an integral risk management plan of drugs and proactive pharmacovigilance of hospital admissions for bleeding associated with apixaban, dabigatran and rivaroxaban from April 2015 through December 2016. Cases were identified using the information management tool of Orion Clinic (hospital electronic medical history) and by reviewing the hospital discharge reports. Various biometric, clinical and pharmacotherapeutic variables of each patient were registered.

Results 37 hospitalisation episodes for DOAC-induced bleeding in 32 patients (15 received rivaroxaban, 9 apixaban and 8 dabigatran) were detected, representing an incidence rate of 3.44 per 100 person-years (95% CI 2.35 to 4.86). The most common bleeding site was gastrointestinal (27 cases, 73.0%). Intracranial bleeding was rare (three cases, 8.1%). Four patients (12.5%) were receiving DOACs at full doses and had a ’dose reduction indication'. The mean (SD) length of stay was 8.4 (5.2) days. Three patients (8.1%) died during the hospitalisation. Among bleeding episodes without fatal outcome, DOACs were stopped in 14 cases, continued in 14 cases, switched for another DOAC in two cases and the dose was reduced in four cases.

Conclusions DOACs are associated with serious bleeding events that require hospitalisation. The risk/benefit ratio assessment considering patient preferences and an individualised follow-up, especially in patients who are elderly, polymedicated or have impaired renal function, can help to reinforce the safe use of DOACs.

  • atrial fibrillation
  • bleeding
  • direct oral anticoagulants
  • gastrointestinal haemorrhage
  • hospitalisation
  • intracranial haemorrhage
  • non–vitamin K antagonist oral anticoagulants
  • pharmacovigilance
  • safety

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.